Use of semaglutide for weight management was associated with reduced triptan consumption during the first year after treatment initiation among women with migraine, according to findings from a nationwide Danish study presented at the European Congress on Obesity 2026. The analysis suggested that semaglutide may reduce the need for acute migraine treatment among individuals with an established migraine history.
Emerging evidence has suggested potential antimigraine effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). In the current nationwide register-based analysis, Anton Pottegård, Noémie Roland, and colleagues evaluated whether semaglutide initiation for weight management influenced use of triptans, a well-established treatment class for acute migraine management.
The study identified all adults in Denmark who initiated semaglutide for weight management between December 1, 2022, and June 30, 2024, using nationwide Danish health registers. The first dispensing date of semaglutide was used as the index date, allowing assessment of triptan use during a 24-month baseline period and 12-month follow-up period. Monthly triptan use was analyzed as defined daily doses (DDDs) per 10,000 individuals. Additional analyses evaluated new triptan users, prevalent users, semaglutide persistence, age, sex, and prior use of prophylactic antimigraine medications.
The cohort included 149,941 individuals initiating semaglutide for weight management. Women represented 69% of the cohort, and the median age was 50 years. Persistent semaglutide users, defined as receiving at least four dispensations during the first year after initiation, accounted for 87% of participants. Approximately 4.6% of individuals received at least one triptan prescription both before and after semaglutide initiation.
Before semaglutide initiation, monthly triptan consumption demonstrated an increasing trend of 7.8 DDDs/month/10,000 individuals. After treatment initiation, the trend gradually reversed, with triptan use decreasing by 14 DDDs/month/10,000 individuals over time. At 12 months, semaglutide initiation was associated with a 7% relative reduction in triptan consumption compared with expected use based on pre-initiation trends.
The reduction was primarily driven by lower triptan use among prevalent users, with a 14% decrease observed at 12 months. In contrast, semaglutide initiation was not associated with reduced numbers of new triptan users, suggesting that treatment may reduce acute migraine medication requirements in individuals with established migraine rather than preventing new migraine onset.
Sex-stratified analyses showed that women experienced an estimated 8% reduction in triptan consumption at 12 months after semaglutide initiation, whereas no statistically significant change was observed among men. The largest reductions were observed among adults aged 18-35 years, with an 18% reduction, and among individuals previously treated with prophylactic antimigraine medications, with a 13% reduction.
The authors noted that several mechanisms could potentially contribute to reduced migraine medication use, including weight loss, improvements in metabolic health, reduced inflammatory activity, and possible direct central nervous system effects of GLP-1 RA therapy. However, they emphasized that the underlying biological mechanisms remain uncertain.
The study used comprehensive nationwide population data, but several limitations were acknowledged. The analysis lacked clinical information such as body weight, weight-loss outcomes, and migraine characteristics. The authors also noted that semaglutide initiation may reflect broader lifestyle and behavioral changes that could have contributed to the observed findings.
The authors concluded: “The study suggests that initiation of semaglutide is associated with a gradual reduction in triptan use during the first year after initiation among women.”
